News Search Results
Jun 30, 2026, 09:00 ET Bota Biosciences and BASF Introduce Bio-Identical Collagen III Powered by AI
market.About Bota BiosciencesBota Biosciences is a global leader in Physical AI-driven biomanufacturing, dedicated to making biotechnology a reliable and scalable engine of productivity. By integrating end-to-end capabilities in AI, synthetic biology, and industrialization, Bota pioneers
More news about: Bota Biosciences
Jun 30, 2026, 08:42 ET Will Therapeutics Announces CQDM-Backed Research Collaboration to Advance First Targeted Pharmacological Treatment for Anorexia Nervosa and Other Compulsive Disorders
MONTRÉAL, June 30, 2026 /PRNewswire/ -- Will Therapeutics, an early-stage biotechnology company developing novel small-molecule medicines for psychiatric and compulsive disorders, today announced that its collaborative research project
More news about: Will Therapeutics
Jun 30, 2026, 08:30 ET FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
HOUSTON, June 30, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts
More news about: FibroBiologics, Inc.
Jun 30, 2026, 08:30 ET Alexandria Real Estate Equities, Inc. Releases 2025 Corporate Responsibility Report Highlighting Strategic Integration of Mission, Innovation and Long-Term Value Creation
and lasting impact on society."More than five decades after Genentech's pioneering work in recombinant DNA technology helped catalyze the biotechnology revolution, the need for innovation to address significant unmet medical need remains immense, with more than 90% of the 10,000 known diseases still
More news about: Alexandria Real Estate Equities, Inc.
Jun 30, 2026, 08:22 ET Martis Capital, Healthcare-Focused PE Firm, Acquires Majority Stake in Healthcare Marketing, Communications, and Media Agency Deerfield Group
GroupDeerfield Group is a fully integrated marketing, media, communications, and technology agency providing innovative solutions for pharmaceutical, biotechnology, health tech, and consumer health companies. Deerfield's solutions are designed to meet the unique needs of healthcare organizations at all stages
More news about: Martis Capital
Jun 30, 2026, 08:00 ET DEERFIELD GROUP ANNOUNCES STRATEGIC INVESTMENT FROM MARTIS CAPITAL TO FUEL NEXT PHASE OF GROWTH
GroupDeerfield Group is a fully integrated marketing, media, communications, and technology agency providing innovative solutions for pharmaceutical, biotechnology, health tech, and consumer health companies. Deerfield's solutions are designed to meet the unique needs of healthcare organizations at all stages
More news about: Deerfield Group
Jun 30, 2026, 07:05 ET Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease
Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, announces cUHDRS subcomponent data from the twelve-month interim
More news about: Skyhawk Therapeutics
Jun 30, 2026, 07:00 ET Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease
Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, announces cUHDRS subcomponent data from the twelve-month interim
More news about: Skyhawk Therapeutics
Jun 30, 2026, 07:00 ET Samsung Biologics Releases 2026 ESG Report, Highlighting Progress in Sustainable Operations and Responsible Growth
chain engagement. The company operated career development programs in partnership with leading educational institutions to help cultivate future biotechnology talent, while also advancing professional growth and leadership opportunities for women in its workforce. The company also expanded supplier sustainability
More news about: Samsung Biologics
Jun 30, 2026, 07:00 ET Muna Therapeutics Announces CEO Transition as Clinical Pipeline Advances
COPENHAGEN, Denmark and BOSTON, June 30, 2026 /PRNewswire/ -- Muna Therapeutics (Muna), a biotechnology company pioneering novel therapeutics for neurodegenerative diseases, today announced a CEO transition. Rita Balice-Gordon, Ph.D., Muna's founding
More news about: Muna Therapeutics
Jun 30, 2026, 06:30 ET Cytonics Completes First-In-Human Phase 1 Clinical Study Report for CYT-108, Advancing Program Toward Next Phase of Development.
of Cytonics. "Advancing a novel biologic from concept through a successful first-in-human clinical trial is a significant achievement for any biotechnology company. The completion of this report provides the foundation for our next regulatory interactions and advances our preparations for additional
More news about: Cytonics Corporation
Jun 30, 2026, 05:37 ET METiS TechBio and Boulevard Bio Enter Global License Agreement for Trispecific T-cell Engager
delivery innovation company, today announced it has entered into an exclusive global licensing agreement with Boulevard Bio ("Boulevard"), a U.S. biotechnology company backed by Deerfield Management, granting Boulevard worldwide development, manufacturing, and commercialization rights for MTS-128, a proprietary
More news about: METiS TechBio
Jun 30, 2026, 04:40 ET Oblique Therapeutics AB Announces Outcome of Rights Issue of SEK 14.1 Million
by both existing and new shareholders through their participation in the rights issue. In a continued challenging financing environment for the biotechnology sector, we view this strong interest as a clear expression of confidence in Oblique Therapeutics, our strategy, and our future prospects.It
More news about: Oblique Therapeutics AB
Jun 30, 2026, 04:39 ET Oblique Therapeutics AB Announces Outcome of Rights Issue of SEK 14.1 Million
by both existing and new shareholders through their participation in the rights issue. In a continued challenging financing environment for the biotechnology sector, we view this strong interest as a clear expression of confidence in Oblique Therapeutics, our strategy, and our future prospects.It
More news about: Oblique Therapeutics AB
Jun 30, 2026, 00:00 ET Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Innovent Biologics
Jun 29, 2026, 19:00 ET Invest SEOUL Joins the World Association of Investment Promotion Agencies (WAIPA)
our global presence and build strong partnerships with member agencies." He added, "Seoul is powered by future strategic industries AI, robotics, biotechnology, quantum computing and Creative Industries as our key growth engines. We look forward to opening new avenues for sustainable investment cooperation
More news about: Invest Seoul
Jun 29, 2026, 16:01 ET FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
June 29, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts
More news about: FibroBiologics, Inc.
Jun 29, 2026, 10:41 ET Plopii Launches Nootropic Nicotine-Free Focus Pouches Powered by Paraxanthine
plopii.com.About PlopiiPlopii is a Brooklyn-based wellness and biotechnology company focused on paraxanthine, caffeine's primary active metabolite. The company develops consumer products and a pharmaceutical pipeline built
More news about: Plopii Inc.
Jun 29, 2026, 10:40 ET Texas Biomed and Flyttr partner to advance next-generation solutions for the invasive New World screwworm
hub for biotechnology and biomedical innovation, driven by a unique concentration of scientific expertise, research infrastructure and collaborative partnerships."I established the Economic Security Advisory Group (ESAG) because San Antonio is uniquely positioned to lead biotechnology efforts,"
More news about: Texas Biomedical Research Institute
Jun 29, 2026, 10:27 ET Plopii Launches Nootropic Nicotine-Free Focus Pouches Powered by Paraxanthine
plopii.com.About PlopiiPlopii is a Brooklyn-based wellness and biotechnology company focused on paraxanthine, caffeine's primary active metabolite. The company develops consumer products and a pharmaceutical pipeline built
More news about: Plopii Inc.
Jun 29, 2026, 09:30 ET NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that its Phase 2b PARADIGM study of PrimeC
More news about: NeuroSense
Jun 29, 2026, 08:45 ET Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Korean Ministry of Intellectual Property (MOIP) has issued Patent
More news about: Anixa Biosciences, Inc.
Jun 29, 2026, 08:33 ET Consano Bio Highlights Scientific Advisory Board for C-1101, a Potential First-in-Class, Non-Opioid Therapy in Development for Chronic Sciatica
Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious painful orthopedic conditions, today highlighted the role of its Scientific Advisory
More news about: Consano Bio
Jun 29, 2026, 07:05 ET REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone
retinal laser; surgical treatment may be required for advanced PDR.2ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Jun 29, 2026, 07:04 ET 37 World's top 2% Scientists participate in Chandigarh University's 10th International Faculty Development Program 2026
intelligence, computer science, management, allied health sciences, architecture, legal studies, liberal arts and humanities, teacher education, biotechnology, pharmacy, data science, sustainability studies, social sciences and other emerging interdisciplinary domains.The 10-day program will feature
More news about: Chandigarh University